EP300 and breast cancer: Indeed, we have previously shown that breast cancer using this compartmentalization process to enhance coactivator recruitment for cytoplasmic localization of CBP/p300-interacting transactivator (CITED) -4, a new member of the CITED family that can compete with HIF-1α for p300, has a worse prognosis [41].